The ability of retinoids to enhance the differentiation of malignant cells is one of their important properties of relevance to cancer prevention and therapy (Sporn & Roberts, 1983) . Alone or as adjuvants to cancer chemotherapy, retinoids exhibit antitumour activities by inhibiting the growth of malignant cells in vivo (Cohen & Carbone, 1972) . They are, in effect, suppressing the phenotypic expression of malignancy by promoting cell differentiation (Sherman et al., 1981) . Various studies suggest that retinoids exert a hormone-like control of either cell proliferation or cell differentiation, or both by acting through specific genetic mechanisms (Astrup & Paulsen, 1982) . Retinoids are also known to affect and modify cell membrane glycosylation and this could result in an alteration in the uptake of nutrients and cytotoxic agents (Lotan, 1980 ). An early report using allogeneic growth of the murine S91 melanoma showed that growth was inhibited by retinyl palmitate (Gainer et al., 1976) whereas other workers have not been able to show an inhibiting effect (Felix et al., 1975) . Meyskens & Salmon (1979) showed that various retinoids including etretinate had inhibitory effects on the colony forming ability of human melanoma in soft agar culture. However, Hoal et al. (1982) reported variable effects that were dependent upon the responsiveness of the cells and not the efficacy of the retinoid. The present work was undertaken to attempt to clarify this paradoxical situation and furthermore, using human material, to obtain results of clinical relevance. 
Vindesine
(23-amino-4-deacetoxy-4-hydroxyvincaleukoblastine sulphate) has been reported to significantly prolong the life of mice bearing the experimental B16 melanoma (Dyke & Nelson, 1977) and has been shown to be clinically active against human malignant melanoma (Retsas et al., 1980; Carmichael et al., 1982 ). The precise mechanism by which vinca alkaloids act is not fully understood although kinetic studies have shown that the vinca alkaloids interfere with mitosis and kill cells which are synthesising DNA (Tucker et al., 1977) . Vindesine has also been shown to inhibit RNA and protein synthesis at concentrations that inhibit cell survival (Hill & Whelan, 1980) . For this study, vindesine was used in combination with the aromatic retinoid, etretinate (Roche 10-9359). Studies were undertake to elucidate the mechanism of action of these substances in combination and as a result suggest possible ways of improving their therapeutic efficacy in the treatment of malignant melanoma.
Materials and methods
The cell lines used, cell culture techniques employed and drug uptake protocol have already been described in detail (Gaukroger et al., 1983 (Gaukroger et al., , 1984 Figure 2 and it can be seen that no ID50 values were determined for the two human melanoma lines. The PG19 murine melanoma however, exhibited greater sensitivity and an ID50 of 1 x 10-6 M was recorded (Table I) . Do values of lxlO-9 (B8), ixlO-9 (B1O) and IxIO-12M (PG19) were recorded (Table I ). ID50 values recorded for continuous contact with the two agents are shown in Table I , and indicate slightly increased sensitivity to the drug combination when compared to vindesine alone.
Vindesine titrations
Cells were grown in the presence of 10 -7 M etretinate and the effect of vindesine on cell survival is shown in Figure 4 . The ID50 concentrations for vindesine are given in Table I (Figure 1 ).
Uptake of labelled drugs 3H-vindesine The uptake profiles of the three cell lines are shown in Figure 6 , and are essentially the same with uptake approaching a plateau between 30 and 40 min from the start of influx measurement. Uptake of 3H-vindesine in the absence of etretinate by the two human melanoma cell lines was identical, but the murine melanoma exhibited saturation of uptake at only 72.1% of this amount (Table II) . Unlabelled etretinate had a minimal stimulatory influence on uptake of 3H-vindesine by the B8 human melanoma, but did elevate the saturable uptake by over 20% for the PGl9 (murine) and BlO (human) melanomas (Table  II) .
3H-etretinate Entry of tritium labelled etretinate by the three cell lines gave virtually identical profiles which are shown in Figure 7 . The uptake of etretinate reached a plateau by 20 min from the start of influx measurements for all the cell lines. The amounts taken by the cell lines are listed in Table III . The addition of vindesine (10-6 M) did not influence the uptake of etretinate by the cells at equilibrium although uptake over the initial period was greater. In contrast, the PG19 murine melanoma took up on average 13.9% more 3H-etretinate than either of the human melanomas (Table III) . In the presence of unlabelled vindesine 3H-etretinate uptake was not altered in any cell line and PG19 3H-etretinate uptake was maintained at 14.4% greater than for either human cell line (Table III) .
Discussion
The most obvious difference between the two agents studied was the lack of cytotoxic effect of etretinate ( Figure 2 ) particularly with regard to the two human melanoma cell lines. This is in agreement with the uptake data which indicates that uptake of 3H-etretinate by the murine melanoma was greater than for either of the human melanomas (Table IV) . In contrast to etretinate all the cell lines were sensitive to vindesine (Figure 1 ). The Do values for the PG19 and BlO cell lines (Table I) Cell volumes were determined using a Coulter Counter (model ZB1) and intracellular drug concentrations calculated assuming that the agents are totally free within the cell. IV). However, the B8 cell line had the greatest sensitivity and the lowest intracellular concentration of vindesine indicating an intrinsic sensitivity to this agent. In the presence of 10-7 M etretinate (which exhibits some degree of toxicity) the Do values for vindesine were decreased (Table I) indicating increased sensitivity, which agrees with the uptake data (Tables II and IV) . In contrast, the ID50 values for vindesine in the presence of 10-' M etretinate were essentially unaltered (Table I ).
In the presence of 10 -I M vindesine ( Figure 5 ) the B8 curve is moved, which indicates that vindesine does not enhance the cytotoxicity of etretinate but that vindesine toxicity is superimposed on that of etretinate. However, vindesine 10-11 M appears to increase the toxicity of etretinate when the survival at 10-6 M is compared for the B8 cells although no similar effect was noted for the other cell lines (Figures 2 and 5 ). Since neither agent stimulated uptake by the B8 cells of the other, this must reflect an intrinsic sensitivity of this cell line to vindesine which is then enhanced at a high concentration of retinoid. In the presence of an equimolar mixture of drugs the Do values for vindesine were variably altered although the ID50 values showed decreases of 4X (PG19), 9X (B8) and 2X for the B1O cells. This would indicate that essentially there is a small synergistic effect with an equimolar mixture.
This work is the first to report, at the cellular and molecular level, on the interactions between vindesine and an aromatic retinoid, etretinate, as a possible form of combination chemotherapy for the treatment of malignant melanoma. (Lotan et al., 1982) and vindesine is reported to kill cells in S phase (Hill & Whelan, 1980) a low etretinate concentration may synchronise cells in G1 and then allow them to progress into S phase where vindesine can exert its toxic effect. A high etretinate concentration may actually maintain cells in G1 and so protect them from vindesine toxicity. It is unlikely that uptake per se can be used to explain the observed differences since efflux of vinca alkaloids is also relevant (Hill et al., 1984) . Rather it is the actual intracellular concentration combined with the intrinsic sensitivity of the cell line that determines the toxic response and the etretinate stimulated uptake of vindesine in the PG19 and B1O cells could account for the enhanced toxic effects. Etretinate taken up by the PG19 cells is present at a 4-5 fold higher concentration than in the B8 or B1O cells and this may account for the greater sensitivity of this cell line. In the presence of 10-7 M etretinate there is increased sensitivity to vindesine (Do). The ID50 value is virtually the same however, which may indicate some stabilising effect of etretinate at a high concentration. This is supported by the reduction of all the ID50 values for the equimolar mixture.
